N-Acetylcysteine Amide against Aβ-Induced Alzheimer's-like Pathology in Rats

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Oxidative stress and glutathione depletion are central to Alzheimer's disease (AD) pathogenesis.
• N-Acetylcysteine (NAC), a glutathione precursor, exhibits neuroprotective properties in AD models.
• N-Acetylcysteine amide (NACA) offers enhanced bioavailability over NAC.

Purpose of the Study:

• To investigate the neuroprotective efficacy of NACA against Aβ1-42 induced AD-like pathology in a rat model.
• To evaluate both restorative and prophylactic administration of NACA.

Main Methods:

• Alzheimer's disease-like pathology was induced via intracerebroventricular Aβ1-42 infusion in Wistar rats.
• NACA was administered either restoratively or prophylactically.
• Cognitive function, neurogenesis, AD markers, oxidative stress, and glial responses were assessed in the hippocampus and prefrontal cortex.

Main Results:

• NACA treatment significantly reversed cognitive deficits and reduced oxidative stress.
• Histopathological and Western blot analyses confirmed NACA's neuroprotective effects, reducing Tau, Aβ, and neurofibrillary tangles.
• NACA administration mitigated astrogliosis and microgliosis, indicating reduced neuroinflammation.

Conclusions:

• N-Acetylcysteine amide (NACA) demonstrates significant neuroprotective effects against Aβ-induced Alzheimer's disease pathology.
• NACA administration ameliorates cognitive decline and oxidative stress, supporting its therapeutic potential for AD.
• The enhanced bioavailability of NACA may contribute to its efficacy in mitigating AD-like symptoms and pathology.